Evofem Biosciences (EVFM) Competitors $0.01 0.00 (0.00%) As of 07/3/2025 11:39 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. MTNB, GLTO, MBIO, SNGX, MBRX, RDHL, INM, TTNP, PLRZ, and EVOKShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Matinas Biopharma (MTNB), Galecto (GLTO), Mustang Bio (MBIO), Soligenix (SNGX), Moleculin Biotech (MBRX), Redhill Biopharma (RDHL), InMed Pharmaceuticals (INM), Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), and Evoke Pharma (EVOK). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors Matinas Biopharma Galecto Mustang Bio Soligenix Moleculin Biotech Redhill Biopharma InMed Pharmaceuticals Titan Pharmaceuticals Polyrizon Evoke Pharma Matinas Biopharma (NYSE:MTNB) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk. Does the media favor MTNB or EVFM? In the previous week, Evofem Biosciences had 1 more articles in the media than Matinas Biopharma. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score. Company Overall Sentiment Matinas Biopharma Neutral Evofem Biosciences Neutral Do institutionals and insiders believe in MTNB or EVFM? 11.8% of Matinas Biopharma shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 4.6% of Matinas Biopharma shares are owned by insiders. Comparatively, 0.2% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better valuation and earnings, MTNB or EVFM? Evofem Biosciences has higher revenue and earnings than Matinas Biopharma. Matinas Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas BiopharmaN/AN/A-$22.94M-$3.86-0.24Evofem Biosciences$11.39M0.10$52.98M-$0.05-0.20 Which has more volatility and risk, MTNB or EVFM? Matinas Biopharma has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500. Do analysts prefer MTNB or EVFM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MTNB or EVFM more profitable? Matinas Biopharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Evofem Biosciences -46.42%-91.97%-61.93% SummaryEvofem Biosciences beats Matinas Biopharma on 7 of the 12 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19M$798.01M$5.53B$9.02BDividend YieldN/A4.84%5.22%3.99%P/E Ratio-0.021.3727.7920.25Price / Sales0.10230.41430.22119.26Price / CashN/A23.4426.2128.59Price / Book0.006.328.035.65Net Income$52.98M-$27.99M$3.18B$249.15M7 Day PerformanceN/A2.32%2.88%2.91%1 Month PerformanceN/A9.07%1.67%4.11%1 Year PerformanceN/A11.51%34.26%20.98% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.592 of 5 stars$0.01flatN/A+4.2%$1.19M$11.39M-0.02120Gap UpMTNBMatinas BiopharmaN/A$0.89-3.3%N/AN/A$4.53MN/A-0.1830Positive NewsGLTOGalecto3.3825 of 5 stars$3.41-0.3%$10.00+193.3%-72.2%$4.52MN/A-0.2240Gap DownMBIOMustang Bio1.0167 of 5 stars$0.96-6.4%N/A-95.1%$4.47MN/A-0.01100SNGXSoligenix1.489 of 5 stars$1.31-3.7%N/A-43.1%$4.44M$120K-0.3120Positive NewsMBRXMoleculin Biotech3.152 of 5 stars$0.30-3.3%$4.00+1,224.9%-90.0%$4.41MN/A0.0020Positive NewsRDHLRedhill BiopharmaN/A$1.94+4.3%N/A-99.1%$4.26M$8.04M0.00210INMInMed Pharmaceuticals1.0328 of 5 stars$3.25-3.8%N/A-44.9%$4.08M$4.60M-0.2710Analyst UpgradeGap DownTTNPTitan Pharmaceuticals0.3015 of 5 stars$4.20-4.5%N/A-14.6%$4.02M$180K-0.9210Gap DownPLRZPolyrizonN/A$0.740.0%N/AN/A$3.94MN/A0.00N/APositive NewsGap DownEVOKEvoke PharmaN/A$2.60-1.1%N/A-58.3%$3.92M$10.25M-0.914Positive News Related Companies and Tools Related Companies Matinas Biopharma Alternatives Galecto Alternatives Mustang Bio Alternatives Soligenix Alternatives Moleculin Biotech Alternatives Redhill Biopharma Alternatives InMed Pharmaceuticals Alternatives Titan Pharmaceuticals Alternatives Polyrizon Alternatives Evoke Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVFM Stock Alerts